219 related articles for article (PubMed ID: 9707022)
1. The use of topical cyclosporin A in ocular graft-versus-host-disease.
Kiang E; Tesavibul N; Yee R; Kellaway J; Przepiorka D
Bone Marrow Transplant; 1998 Jul; 22(2):147-51. PubMed ID: 9707022
[TBL] [Abstract][Full Text] [Related]
2. Ocular manifestations of graft versus host disease following bone marrow transplantation.
Claes K; Kestelyn P
Bull Soc Belge Ophtalmol; 2000; (277):21-6. PubMed ID: 11126670
[TBL] [Abstract][Full Text] [Related]
3. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
Epstein JB; Reece DE
Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
[TBL] [Abstract][Full Text] [Related]
4. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
6. Clinical review: topical ophthalmic use of cyclosporin A.
Utine CA; Stern M; Akpek EK
Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Malta JB; Soong HK; Shtein RM; Musch DC; Rhoades W; Sugar A; Mian SI
Cornea; 2010 Dec; 29(12):1392-6. PubMed ID: 20847658
[TBL] [Abstract][Full Text] [Related]
8. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
9. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation.
Karwacka E; Ołdakowska-Jedynak U; Brydak-Godowska J; Paczek L; Kecik D
Transplant Proc; 2006; 38(1):292-4. PubMed ID: 16504728
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment.
Spiryda LB; Laufer MR; Soiffer RJ; Antin JA
Biol Blood Marrow Transplant; 2003 Dec; 9(12):760-5. PubMed ID: 14677115
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
12. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal.
Oliveira JS; Bahia D; Franco M; Balda C; Stella S; Kerbauy J
Bone Marrow Transplant; 1999 Jan; 23(1):99-101. PubMed ID: 10037059
[TBL] [Abstract][Full Text] [Related]
13. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic cyclosporine use in ocular GVHD.
Lelli GJ; Musch DC; Gupta A; Farjo QA; Nairus TM; Mian SI
Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
[TBL] [Abstract][Full Text] [Related]
15. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
16. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
17. Topical tacrolimus--a novel treatment alternative for cutaneous chronic graft-versus-host disease.
Elad S; Or R; Resnick I; Shapira MY
Transpl Int; 2003 Sep; 16(9):665-70. PubMed ID: 12768230
[TBL] [Abstract][Full Text] [Related]
18. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
20. [Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study].
Reinhard T; Reis A; Mayweg S; Oberhuber H; Mathis G; Sundmacher R
Klin Monbl Augenheilkd; 2002 Mar; 219(3):125-31. PubMed ID: 11987039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
